Takeda to build €40m Irish plant for global Ninlaro API supply

By Dan Stanton contact

- Last updated on GMT

Image: iStock/masterSergeant
Image: iStock/masterSergeant

Related tags: Multiple myeloma

Takeda will build a high containment production facility at its site in Dublin, Ireland to support the manufacturing of its oncology product Ninlaro (ixazomib).

The Japanese pharma firm announced today it is investing €40m ($43m) and creating 40 new jobs at the site in Grange Castle, Dublin in order to support global supply of its cancer drug Ninlaro.

The proteasome inhibitor works by blocking enzymes from multiple myeloma cells, hindering their ability to grow and survive, and was approved by the US Food and Drug Administration (FDA) in November 2015 for patients with multiple myeloma who have received at least one prior therapy.

Paul Keogh, Plant Director at Takeda Ireland Grange Castle said the site has “been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide.

“We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site.”

The new facility will be a standalone high containment production facility dedicated to manufacturing the product.

The site, located about 10km west of the Irish capital, was established in 2002 as Takeda’s worldwide centre for Active Pharmaceutical Ingredient (API) manufacturing, with commercial production for the firm’s diabetes drug Actos (pioglitazone) commencing in 2007.

It is one of two Takeda sites in Ireland, the other a manufacturing and packaging site located in Bray just south of Dublin.

The news was welcomed by Ireland’s development agency (IDA) who described the investment as “a great win and vote of confidence”​ in the country.

The news is the second facility investment announced by Takeda in the past few days. The firm said it began construction of a Dengue fever virus vaccine plant in Singen, Germany last week​ at a cost of $100m.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us


View more